Mr Justice Birss Topic Paragraph Introduction 1 The issues 5 The witnesses 32 Technical Background 53 The 181 Patent 72 72 The skilled person and the common general knowledge – 181 99 The 181 patent specification 117 Claim construction - 181 138 Priority -181 143 The priority document 160 Is the Named Compound tadalafil? 192 What are compounds 1 to 5? 211 Ranges 228 Priority overall 235 Added matter - 181 238 Novelty - 181 257 Obviousness 181 – 287 Obviousness the facts – 343 Insufficiency - 181 346 Infringement - 181 The 092 Patent 357 357 The skilled person and the common general knowledge – 092 377 The 092 patent specification 385 Claim construction - 092 392 Priority -092 395 Added matter - 092 400 Novelty - 092 410 Obviousness 092 – 459 Insufficiency - 092 460 Claims limited by pharmacokinetic properties 468 12 469 Claims 1 to7 – particle size distribution 490 Infringement - 092 Conclusion 491 1 relevant claims of the 181 patent – Annex 2 relevant claims of the 092 patent – Introduction These action is concerned with patents relating to tadalafil. Tadalafil is the generic name for a product sold under the brand name CIALIS for male erectile dysfunction and under the brand name ADCIRCA for pulmonary arterial hypertension. CIALIS is also sold for benign prostatic hyperplasia. The patents and exclusive licences are held
Mr Justice Birss Topic Paragraph Introduction 1 The issues 5 The witnesses 32 Technical Background 53 The 181 Patent 72 The skilled person and the common general knowledge – 181 72 The 181 patent specification 99 Claim construction - 181 117 Priority -181 138 The priority document 143 Is the Named Compound tadalafil? 160 What are compounds 1 to 5? 192 Ranges 211 Priority overall 228 Added matter - 181 235 Novelty - 181 238 Obviousness – 181 257 Obviousness – the facts 287 Insufficiency - 181 343 Infringement - 181 346 The 092 Patent 357 The skilled person and the common general knowledge – 092 357 The 092 patent specification 377 Claim construction - 092 385 Priority -092 392 Added matter - 092 395 Novelty - 092 400 Obviousness – 092 410 Insufficiency - 092 459 Claims limited by pharmacokinetic properties 460 12 468 Claims 1 to7 – particle size distribution 469 Infringement - 092 490 Conclusion 491 1 – relevant claims of the 181 patent Annex 2 – relevant claims of the 092 patent Introduction These action is concerned with patents relating to tadalafil. Tadalafil is the generic name for a product sold under the brand name CIALIS for male erectile dysfunction and under the brand name ADCIRCA for pulmonary arterial hypertension. CIALIS is also sold for benign prostatic hyperplasia. The patents and exclusive licences are held